Top Markets
Coin of the day
Merck & Co., Inc. Merck & Co., Inc.

Merck & Co., Inc.

MRK
Clasificación en acciones #40
Merck & Co., Inc. is a global healthcare leader with operations spanning two... Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
Precio por acción
$152.37
Capitalización bursátil
$376.33B
Cambio (1 día)
12.46%
Cambio (1 año)
79.41%
País
US
Comercio Merck & Co., Inc. (MRK)

Categoría

Ratio P/E de Merck & Co., Inc. (MRK)
Ratio P/E al August 2026 TTM: 107.81
Según los últimos informes financieros y el precio de las acciones de Merck & Co., Inc., el P/E actual (TTM) de la empresa es 107.81. Al final de 2024, la empresa tenía un P/E de 14.72.
Historial del ratio P/E de Merck & Co., Inc. desde 2000 hasta 2026
Relación P/E al final de cada año
Año Ratio P/E Cambiar
2026 (TTM) 107.81 645.57%
2025 14.46 -1.74%
2024 14.72 -98.11%
2023 778.71 3,924.61%
2022 19.35 30.21%
2021 14.86 -46.79%
2020 27.92 23.57%
2019 22.60 -25.59%
2018 30.37 -49.75%
2017 60.43 53.54%
2016 39.36 24.80%
2015 31.54 144.60%
2014 12.89 -59.36%
2013 31.72 65.59%
2012 19.16 9.91%
2011 17.43 -85.89%
2010 123.55 2,069.42%
2009 5.70 -28.19%
2008 7.93 -78.40%
2007 36.72 79.85%
2006 20.42 41.90%
2005 14.39 23.34%
2004 11.67 -19.12%
2003 14.42 -15.38%
2002 17.04 -3.27%
2001 17.62 -41.63%
2000 30.19 0.00%
Relación P/E para empresas similares o competidores
Empresa P/E Ratio Diferencia del P/E Ratio País
39.54 -63.33%
US
30.10 -72.08%
US
70.28 -34.81%
US
22.25 -79.36%
CH
22.23 -79.38%
CH
¿Cómo leer un P/E ratio?

El ratio Precio/Beneficio (P/E Ratio) mide la relación entre el precio de las acciones de una empresa y sus beneficios por acción.
Un P/E bajo pero positivo indica una empresa con altos beneficios en relación a su valoración actual y que podría estar infravalorada. Una empresa con un P/E negativo alto (cerca de 0) indica fuertes pérdidas en comparación con su valoración.

Las empresas con un P/E superior a 30 o negativo suelen considerarse "acciones de crecimiento", lo que significa que los inversores esperan que crezca o se vuelva rentable en el futuro.

Las empresas con un P/E positivo inferior a 10 suelen considerarse "acciones de valor", lo que significa que ya son muy rentables y no se espera un fuerte crecimiento.